Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomarker Consortium launches

This article was originally published in The Gray Sheet

Executive Summary

The American College of Radiology Imaging Network's (ACRIN) planned clinical trial exploring the use of fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate non-Hodgkins lymphoma and lung cancer patients' response to therapy is the first project supported by the Biomarker Consortium, a newly formed research partnership between the Foundation for the National Institutes of Health, NIH, FDA, CMS and industry and patient groups, according to an Oct. 5 release. The consortium will identify and validate new biological markers to advance the science of personalized medicine. "Imaging tests such as PET scanning can potentially reduce both suffering and cost for cancer patients by providing better selection of appropriate treatment and determining earlier ... whether treatment will be effective," ACRIN explains. Depression and diabetes are further areas of prospective study cited by the consortium...

You may also be interested in...

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

Mallinckrodt Finds An Exit Door For Generics In Proposed Opioid Settlement

The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts